PRDX2 and ovarian cancer: An interesting study reported enhanced efficacy of a combination of TsA and 5-aza-2`-deoxycitidine (DNA-methyltransferase inhibitor) and low-dose cisplatin in comparison to single drug in vitro as measured by decreased ovarian cancer cell line cell viability, migration and spheroid growth [44].